Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract Proteasome-catalyzed peptide splicing represents an additional catalytic activity of proteasomes contributing to the pool of MHC-class I-presented epitopes. We here biochemically and functionally characterized a new melanoma gp100 derived spliced epitope. We demonstrate that the gp100 mel 47–52/40–42 antigenic peptide is generated in vitro and in cellulo by a not yet described proteasomal condensation reaction. gp100 mel 47–52/40–42 generation is enhanced in the presence of the β5i/LMP7 proteasome-subunit and elicits a peptide-specific CD8 + T cell response. Importantly, we demonstrate that different gp100 mel -derived spliced epitopes are generated and presented to CD8 + T cells with efficacies comparable to non-spliced canonical tumor epitopes and that gp100 mel -derived spliced epitopes trigger activation of CD8 + T cells found in peripheral blood of half of the melanoma patients tested. Our data suggest that both transpeptidation and condensation reactions contribute to the frequent generation of spliced epitopes also in vivo and that their immune relevance may be comparable to non-spliced epitopes.

More information Original publication

DOI

10.1038/srep24032

Type

Journal article

Publisher

Springer Science and Business Media LLC

Publication Date

2016-04-06T00:00:00+00:00

Volume

6